文献速递乳腺癌支持与姑息治疗

2型糖尿病、二甲双胍使用与乳腺癌风险的前瞻性研究

A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
PubMed 文献 · Ann Oncol · 2021-01-29

该研究基于44 541名Sister Study参与者,中位随访8.6年,发现2型糖尿病与乳腺癌总体风险无关(HR 0.99),但二甲双胍使用与ER阳性乳腺癌风险降低相关(HR 0.86),且与三阴性乳腺癌风险升高相关(HR 1.74)。长期(≥10年)二甲双胍使用与ER阳性乳腺癌风险降低更明显(HR 0.62)。

要点

  • 2型糖尿病与乳腺癌总体风险无关,但三阴性乳腺癌风险可能升高。
  • 二甲双胍使用与ER阳性乳腺癌风险降低相关,且长期使用关联更强。
  • 二甲双胍使用与三阴性乳腺癌风险升高相关,需进一步验证。

核心结论

  • 2型糖尿病与乳腺癌的关联可能因激素受体状态而异,长期二甲双胍使用可能降低ER阳性乳腺癌风险。

研究设计与样本

  • 前瞻性队列研究,纳入44 541名35-74岁Sister Study参与者,随访至2017年9月15日,中位随访8.6年。

主要发现

  • 随访期间诊断2678例乳腺癌,2型糖尿病与乳腺癌总体风险无关(HR 0.99;95%CI 0.87-1.13)。
  • 2型糖尿病与三阴性乳腺癌风险升高相关(HR 1.40;95%CI 0.90-2.16)。
  • 二甲双胍使用与ER阳性乳腺癌风险降低相关(HR 0.86;95%CI 0.70-1.05),与ER阴性(HR 1.25;95%CI 0.84-1.88)及三阴性乳腺癌(HR 1.74;95%CI 1.06-2.83)风险升高相关。
  • 长期(≥10年)二甲双胍使用与ER阳性乳腺癌风险降低更明显(HR 0.62;95%CI 0.38-1.01;P for trend=0.09)。

临床怎么用

  • 对于2型糖尿病合并乳腺癌高危因素的女性,长期二甲双胍使用可能与ER阳性乳腺癌风险降低相关,但需权衡三阴性乳腺癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk. Few studies have investigated T2D and medications together in relation to breast cancer. PATIENTS AND METHODS: Data came from 44 541 Sister Study participants aged 35 to 74 years at enrollment (2003-2009) who satisfied eligibility criteria, followed through 15 September 2017. Information on time-varying, self-reported, physician-diagnosed, prevalent and incident T2D, use of antidiabetic medications, and covariates was obtained from baseline and follow-up questionnaires. Incident breast cancers were confirmed with medical records. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. RESULTS: During follow-up (median, 8.6 years), 2678 breast cancers were diagnosed at least 1 year after enrollment. There were 3227 women (7.2%) with prevalent and 2389 (5.3%) with incident T2D, among whom 61% (n = 3386) were ever treated with metformin. There was no overall association between T2D and breast cancer risk (HR 0.99; 95% CI, 0.87-1.13). However, T2D was associated with increased risk of triple-negative breast cancer (HR 1.40; 95% CI, 0.90-2.16). Compared with not having T2D, T2D with metformin use was not associated with overall breast cancer risk (HR 0.98; 95% CI, 0.83-1.15), but it was associated with decreased risk of estrogen receptor (ER)-positive breast cancer (HR 0.86; 95% CI 0.70-1.05) and increased risk of ER-negative (HR 1.25; 95% CI, 0.84-1.88) and triple-negative breast cancer (HR 1.74; 95% CI, 1.06-2.83). The inverse association with ER-positive cancer was stronger for longer duration (≥10 year) metformin use (HR 0.62; 95% CI, 0.38-1.01; P for trend = 0.09). Results were supported by sensitivity analyses. CONCLUSION: Our findings suggest that associations between T2D and breast cancer may differ by hormone receptor status and that associations between T2D and ER-positive breast cancer may be reduced by long-term metformin use.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Park YM, Bookwalter DB, O'Brien KM, et al. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol. 2021. PMID: 33516778. doi:10.1016/j.annonc.2020.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。